BIODESIX INC

Biodesix insider buying signals confidence and upside potential—Schuler adds 15k shares, analysts lift target to $35, and the 52‑week high fuels bullish sentiment.

Insider buying by Jack W Schuler at Biodesix signals confidence in its lung‑cancer diagnostics pipeline, suggesting a potential buying opportunity for investors.